Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors

Cancer Research

Volumn 64, Issue 11, 2004, Pages 3731-3736

  Tong, Ricky T ^a,b   Boucher, Yves ^a   Kozin, Sergey V ^a   Winkler, Frank ^a   Hicklin, Daniel J ^c   Jain, Rakesh K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY DC101; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 2 ANTIBODY;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; BLOOD VESSEL WALL; CELL FUNCTION; CELL MATURATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROSTATIC PRESSURE; LYMPHATIC SYSTEM; MOUSE; NONHUMAN; PRESSURE GRADIENT; PRIORITY JOURNAL; PROCESS DESIGN; RECEPTOR BLOCKING; SOLID TUMOR; SURVIVAL RATE; TISSUE PRESSURE; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIBODIES; CAPILLARY PERMEABILITY; CELL LINE, TUMOR; HUMANS; HYDROSTATIC PRESSURE; MICE; MICE, SCID; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SERUM ALBUMIN, BOVINE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 2542628099     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0074     Document Type: Article

References (31)

1. McCarthy M. Antiangiogenesis drug promising for metastatic colorectal cancer. Lancet 2003;361:1959.
2. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-9.
3. Lee CG, Heijn M, di Tomaso E, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000;60:5565-70.
4. Willett CG, Boucher Y, Di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-7.
5. Leu AJ, Berk DA, Lymboussaki A, Alitalo K, Jain RK. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res 2000;60:4324-7.
6. Padera TP, Kadambi A, di Tomaso E, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science (Wash DC) 2002;296:1883-6.
7. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003;9:685-93.
8. Boucher Y, Jain RK. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res 1992;52:5110-4.
9. Stohrer M, Boucher Y, Stangassinger M, Jain RK. Oncotic pressure in solid tumors is elevated. Cancer Res 2000;60:4251-5.
10. Kozin SV, Boucher Y, Hicklin DJ, Bohlen P, Jain RK, Suit HD. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res 2001;61:39-44.
11. Brown EB, Campbell RB, Tsuzuki Y, et al. In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy. Nat Med 2001;7:864-8.
12. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 1996;93:14765-70.
13. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002;160:985-1000.
14. Boucher Y, Kirkwood JM, Opacic D, Desantis M, Jain RK. Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res 1991;51:6691-4.
15. Leunig M, Yuan F, Menger MD, et al. Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice. Cancer Res 1992;52:6553-60.
16. Peters W, Teixeira M, Intaglietta M, Gross JF. Microcirculatory studies in rat mammary carcinoma. I. Transparent chamber method, development of microvasculature, and pressures in tumor vessels J Natl Cancer Inst (Bethesda) 1980;65:631-42.
17. Abramsson A, Lindblom P, Betsholtz C. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Investig 2003;112:1142-51.
18. Jain RK. Transport of molecules across tumor vasculature. Cancer Metastasis Rev 1987;6:559-93.
19. Dvorak HF, Nagy JA, Feng D, Dvorak HF. Tumor architecture and targeted delivery. In: Abrams PG, Fritzberg AR, editors. Radioimmunotherapy of cancer. New York: Marcel Dekker; 2002. p. 107-35.
20. Netti PA, Hamberg LM, Babich JW, et al. Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc Natl Acad Sci USA 1999;96:3137-42.
21. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Investig 1999;103:159-65.
22. Netti PA, Roberge S, Boucher Y, Baxter LT, Jain RK. Effect of transvascular fluid exchange on pressure-flow relationship in tumors: a proposed mechanism for tumor blood flow heterogeneity. Microvasc Res 1996;52:27-46.
23. Baish JW, Netti PA, Jain RK. Transmural coupling of fluid flow in microcirculatory network and interstitium in tumors. Microvasc Res 1997;53:128-41.
24. Parker JC, Perry MA, Taylor AE. Permeability of the microvascular barrier. In: Staub NC, Taylor AE, editors. Edema. New York: Raven Press; 1984. p. 143-87.
25. Aukland K, Reed RK. Interstitial-lymphatic mechanisms in the control of extracellular fluid volume. Physiol Rev 1993;73:1-78.
26. Hobbs SK, Monsky WL, Yuan F, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 1998;95:4607-12.
27. Wildiers H, Guetens G, De Boeck G, et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 2003;88:1979-86.
28. Teicher BA. A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics → mechanism(s) of interaction). Cancer Metastasis Rev 1996;15:247-72.
29. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-86.
30. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Investig 2000;105:R15-24.
31. Baker CH, Solorzano CC, Fidler IJ. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res 2002;62:1996-2003.